Siponimod

西尼莫德

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NameSiponimod
Drug Alias NameSiponimodum司珀莫德辛波莫德MayzentBAF-312 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSphingosine 1-Phosphate Receptor 1 modulatorsSphingosine 1-phosphate receptor 5 modulators
TargetsSphingosine 1-phosphate receptor 5Sphingosine 1-Phosphate Receptor 1
Therapy Area/IndicationsHemorrhagic StrokeCognitive DysfunctionAlzheimer Disease +[10] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2019/03/26
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgNovartis Pharma Stein AgNovartis Europharm Ltd
Inactive CompaniesBeijing Novartis Pharma Co Ltd
Active IndicationsCognitive DysfunctionAlzheimer DiseaseMultiple Sclerosis, Relapsing-Remitting +[5] 
Inactive IndicationsHemorrhagic StrokeCerebral HemorrhageHepatic Insufficiency +[5] 

Other Information

ATC CodeL04AE03
Related LinksWikipediaDrugBankKEGG